U.S. flag

An official website of the United States government

NM_000138.5(FBN1):c.4204T>C (p.Cys1402Arg) AND Familial thoracic aortic aneurysm and aortic dissection

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Dec 5, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002327894.2

Allele description [Variation Report for NM_000138.5(FBN1):c.4204T>C (p.Cys1402Arg)]

NM_000138.5(FBN1):c.4204T>C (p.Cys1402Arg)

Gene:
FBN1:fibrillin 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
15q21.1
Genomic location:
Preferred name:
NM_000138.5(FBN1):c.4204T>C (p.Cys1402Arg)
HGVS:
  • NC_000015.10:g.48474261A>G
  • NG_008805.2:g.176528T>C
  • NM_000138.5:c.4204T>CMANE SELECT
  • NM_001406716.1:c.4204T>C
  • NP_000129.3:p.Cys1402Arg
  • NP_000129.3:p.Cys1402Arg
  • NP_001393645.1:p.Cys1402Arg
  • LRG_778t1:c.4204T>C
  • LRG_778:g.176528T>C
  • LRG_778p1:p.Cys1402Arg
  • NC_000015.9:g.48766458A>G
  • NM_000138.4:c.4204T>C
Protein change:
C1402R
Molecular consequence:
  • NM_000138.5:c.4204T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001406716.1:c.4204T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Familial thoracic aortic aneurysm and aortic dissection (TAAD)
Synonyms:
Thoracic aortic aneurysm and aortic dissection; Thoracic aortic aneurysms and dissections
Identifiers:
MONDO: MONDO:0019625; MedGen: C4707243; Orphanet: 91387; OMIM: PS607086

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002630674Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Likely pathogenic
(Dec 5, 2017)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes.

Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U.

Am J Hum Genet. 1999 Oct;65(4):1007-20.

PubMed [citation]
PMID:
10486319
PMCID:
PMC1288233

Erratum: Detection of six novel FBN1 mutations in British patients affected by Marfan syndrome.

Comeglio P, Evans AL, Brice GW, Child AH.

Hum Mutat. 2001 Dec;18(6):546-7.

PubMed [citation]
PMID:
11748851
See all PubMed Citations (4)

Details of each submission

From Ambry Genetics, SCV002630674.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

The p.C1402R variant (also known as c.4204T>C), located in coding exon 33 of the FBN1 gene, results from a T to C substitution at nucleotide position 4204. The cysteine at codon 1402 is replaced by arginine, an amino acid with highly dissimilar properties, and is located in the cb EGF-like #19 domain. The majority of FBN1 mutations identified to date have involved the substitution or generation of cysteine residues within cbEGF domains (Vollbrandt T et al. J Biol Chem. 2004;279(31):32924-32931). This alteration has been detected in patients with Marfan syndrome, including one reported de novo case (Arbustini E et al. Hum. Mutat., 2005 Nov;26:494; Pees C et al. Clin. Genet., 2014 Dec;86:552-7). In addition, alternate amino acid substitutions at this position, p.C1402Y and p.C1402W, have also been reported in individuals with Marfan syndrome (Schrijver I et al. Am. J. Hum. Genet., 1999 Oct;65:1007-20; Comeglio P et al. Hum. Mutat., 2001 Dec;18:546-7). Based on internal structural assessment, these alterations eliminate a structurally critical disulfide bond in cbEGF domain #19. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis.Based on the majority of available evidence to date, this variant is likely to be pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 1, 2024